Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy

Authors

  • Arun HS Kumar School of Veterinary Medicine, University College Dublin, Belfield, Dublin-04, IRELAND.

DOI:

https://doi.org/10.5530/bems.7.2.8

Keywords:

Molecular interaction, Protease inhibitor, SARS-CoV-2, Antiviral, Coronavirus

Abstract

Introduction: Orally bioavailable SARS-CoV-2 antiviral drugs will significantly improve the clinical management of the disease. PF07321332 (PF32) one such orally bioavailable SARSCoV- 2 protease inhibitor which can be helpful to prevent viral replication in the host. Materials and Methods: Hence this study evaluated the network pharmacology of PF32 using established methods to predict its potential safety and efficacy. Results: PF32 was selective against SARS-CoV-2 proteases without any affinity against SARS-CoV-2 RNA polymerase or its spike protein. While PF32 showed pharmacologically relevant affinity against several targets in human tissues. The target profiling of PF32 indicated a fourfold selectivity towards several proteases in human tissues with an affinity (IC50) ranging from 26 to 41 nM. Conclusion: The predicted inhibitory effects of PF32 against both host and viral proteases may have synergistic effects for superior clinical efficacy.

Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy

Downloads

Published

2021-10-25

How to Cite

Kumar, A. H. (2021). Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy. Biology, Engineering, Medicine and Science Reports, 7(2), 21–24. https://doi.org/10.5530/bems.7.2.8

Issue

Section

Research Article

Most read articles by the same author(s)